Evobrutinib

  Cat. No.:  DC10380   Featured
Chemical Structure
1415823-73-2
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Evobrutinib is an inhibitor of Bruton's tyrosin kinase (Btk) inhibitor extracted from patent US20140162983 example 0174.
Cas No.: 1415823-73-2
Chemical Name: Evobrutinib
Synonyms: Evobrutinib;M2951;MSC2364447C;1-[4-[[[6-Amino-5-(4-phenoxyphenyl)-4-pyrimidinyl]amino]methyl]-1-piperidinyl]-2-propen-1-one;1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one;ZA45457L1K;1-(4-(((6-Amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-2-propen-1-one;1-[4-({[6-AMINO-5-(4-PHENOXYPHENYL)PYRIMIDIN-4-YL]AMINO}METHYL)PIPERIDIN-1-YL]PROP-2-EN-1-ONE;1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]met
SMILES: O=C(C([H])=C([H])[H])N1C([H])([H])C([H])([H])C([H])(C([H])([H])N([H])C2C(=C(N([H])[H])N=C([H])N=2)C2C([H])=C([H])C(=C([H])C=2[H])OC2C([H])=C([H])C([H])=C([H])C=2[H])C([H])([H])C1([H])[H]
Formula: C25H27N5O2
M.Wt: 429.5142
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Evobrutinib is an inhibitor of Bruton's tyrosin kinase (Btk) inhibitor extracted from patent US20140162983 example 0174.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC5146 RN486 RN-486 is a Bruton's tyrosine kinase (Btk) inhibitor.
DC10380 Evobrutinib Evobrutinib is an inhibitor of Bruton's tyrosin kinase (Btk) inhibitor extracted from patent US20140162983 example 0174.
DC12030 BMS-986195 BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK).
DC11819 BMS-986142 BMS-986142 is a potent, selective, and reversible BTK (Bruton’s tyrosine kinase) inhibitor (BTK IC₅₀ = 0.5nM; human WB IC₅₀ = 90 nM).
DC5014 AVL-292 AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk currently being evaluated in a Phase 1b clinical trial in relapsed.
X